Q1 2021 13F Holders as of 3/31/2021
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
40.6M
-
Number of holders
-
81
-
Total 13F shares, excl. options
-
14.4M
-
Shares change
-
-1.61M
-
Total reported value, excl. options
-
$886M
-
Value change
-
-$122M
-
Number of buys
-
45
-
Number of sells
-
-36
-
Price
-
$61.55
Significant Holders of Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) as of Q1 2021
95 filings reported holding KROS - Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share as of Q1 2021.
Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) has 81 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 14.4M shares
of 40.6M outstanding shares and own 35.46% of the company stock.
Largest 10 shareholders include FMR LLC (2.93M shares), ORBIMED ADVISORS LLC (1.68M shares), Foresite Capital Management IV, LLC (1.38M shares), BlackRock Inc. (1.22M shares), Consonance Capital Management LP (890K shares), STATE STREET CORP (724K shares), VANGUARD GROUP INC (603K shares), ALKEON CAPITAL MANAGEMENT LLC (523K shares), Nantahala Capital Management, LLC (460K shares), and EVENTIDE ASSET MANAGEMENT, LLC (427K shares).
This table shows the top 81 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.